Rapid Vaccine Development Using Molecular Clamp

Vaccine

Research Institution

University of Queensland

Description

The University of Queensland has been asked to develop a vaccine for the recent coronavirus outbreak at unprecedented speed, using new technology. The Coalition for Epidemic Preparedness Innovations (CEPI) has requested the University use its recently developed rapid response technology to develop a new vaccine, which could be available worldwide in as little as six months.

Head of University's School of Chemistry and Molecular Biosciences, Professor Paul Young said The University of Queensland had novel technology for the rapid generation of new vaccines from the knowledge of a virus’s genetic sequence information.

Dynavax has announced a partnership with the University of Queensland to develop a vaccine to prevent COVID-19 using its toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018. The partnership is part of the Coalition for Epidemic Preparedness (CEPI) initiative.

CpG 1018 is an adjuvant used in Dynavax’s FDA-approved hepatitis B vaccine, HEPLISAV-B®.

Research Team

David Paterson
Director at The University of Queensland Centre for Clinical Research
University of Queensland
Paul Young
Head of School of Chemistry and Molecular Biosciences
University of Queensland

Project Details

Funding Sources

CEPI, The Queensland Government, Paul Ramsay Foundation, a2 Milk Company

Project Phases

Planned Time to Trials

Needs

Hover for more information.
No items found.

Get In Touch

Directly connect with the responsible researchers by sending a message.
Thank you! Your message has been received and will be forwarded to the research team!
Oops! Something went wrong while submitting the form.